Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

UNCOVERED: Compass pathways - Caught on Camera

Cathie Wood Bets $19 Million on 5 Beaten-Down Stocks

Cathie Woods’s ARK Invest deploys $19 million across five growth stocks in this uncertain market.

Barchart

Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise

See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup.

MarketBeat

This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip?

Compass Pathways took a 50% on June 23 hit after a lukewarm trial, but long-term bulls see upside in psychedelics.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Compass Pathways Stock Is Plunging Today: What's Going On?

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met lofty investor expectations.

Benzinga

Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.1% on Monday.

Benzinga

1 Biotech Stock Under $10 That Could Surge 420%

Down 84% from all-time highs, Compass Pathways is a beaten-down biotech stock that trades at a massive discount to consensus price target estimates in 2024.

Barchart

World's largest trial into whether magic mushrooms can treat depression launched at London hospital

Scientists hail 'milestone' in mental health research as new site opens at Maudsley hospital in Camberwell

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Is the therapeutic potential of hallucinogens risky and overhyped?

As the medicinal use of psychedelics gains mainstream attention, fears remain over their effect on mental health and the need for safe administration

The Guardian - UK

Magic mushroom ingredient could help treat anorexia, research suggests

A single dose of the psychedelic, given alongside psychological support, is a safe and acceptable treatment for the condition, a study suggests

The Independent UK

Psilocybin may be a potential treatment for anorexia, research suggests

A single dose of the psychedelic, given alongside psychological support, is a safe and acceptable treatment for the condition, a study suggests.

The Independent UK

Magic mushrooms compound ‘effective at treating depression in cancer patients’

Largest ever trial of psilocybin offers hope of treatment to cancer patients with major depressive disorder

Evening Standard

Anorexia is the deadliest psychiatric disorder. Could psychedelics help?

A Nasdaq-listed company is trialling the active ingredient in magic mushrooms as a new treatment

Financial Times

A 36-year-old CEO saw how psychedelics treated his best friend’s mental illness. Now his Peter Thiel-funded firm wants to bring the drugs to the masses

Florian Brand's Atai Life Sciences went public three years after launching, fueled by Silicon Valley interest and promising science, but it's still waiting for its first big breakthrough.

Fortune

A single dose of psilocybin may alleviate major depression for 12 weeks, study finds

A psilocybin-based drug for treatment-resistant depression may be one step closer to approval, researchers say.

Inverse

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

COMPASS Pathways Shares Q3 2022 Financial Results, Business News & Term's Highlights

Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and business developments.

Evening Standard

Magic mushrooms compound found to ‘significantly reduce’ depression symptoms in major trial

Psilocybin has been found to have a positive impact on patients suffering from treatment-resistant depression

The Independent UK

Magic-mushroom drug can reduce depression symptoms, study suggests

Psychedelic effects lasted between six to eight hours, and during this time a therapist was in the room to provide psychological support.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Upgrades

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Compass Pathways Will Lead Two Concurrent Phase 3 Trials On Psilocybin-Assisted Therapy For Depression

Psychedelics biotech company Compass Pathways (NASDAQ: CMPS) announced it will conduct two separate Phase 3 clinical trials to study psilocybin-assisted therapy on Treatment-Resistant Depression (TRD),

Benzinga

Psychedelics Sector Poised To Soar If Compass Pathway's Chart Breaks This Pattern

Compass Pathways (NASDAQ: CMPS) has been trading relatively stronger than the S&P 500 recently, in a mostly sideways consolidation pattern compared to the market ETF, which entered into a steep downtrend on Aug. 16.

Benzinga

Psychedelics Management Updates: Two Top Companies Appoint New CEOs, Here's What We Know

Two companies in the psychedelics space have chosen new chief executive officers: COMPASS Pathways (NASDAQ: CMPS) has chosen Kabir Nath, and Small Pharma will be now led by George Tziras.

Benzinga

Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 6.63% at $0.71

Benzinga

US Senate Moves Forward On Gun Reform: 3 Stocks That Could Benefit As A Result

Tuesday night, the U.S. Senate finally cleared a procedural vote to move forward with gun control legislation. The action comes after weeks of negotiations.

Benzinga

Psychedelic Stock Gainers And Losers From June 14, 2022

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 9.90% at $9.44

Benzinga

ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 1.06% at $0.81 LOSERS:

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

University of Edinburgh

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.